NO944752D0 - Rensede DNase-former - Google Patents

Rensede DNase-former

Info

Publication number
NO944752D0
NO944752D0 NO944752A NO944752A NO944752D0 NO 944752 D0 NO944752 D0 NO 944752D0 NO 944752 A NO944752 A NO 944752A NO 944752 A NO944752 A NO 944752A NO 944752 D0 NO944752 D0 NO 944752D0
Authority
NO
Norway
Prior art keywords
components
deamidated
species
purified
purified dnase
Prior art date
Application number
NO944752A
Other languages
English (en)
Other versions
NO944752L (no
NO318644B1 (no
Inventor
John Frenz
Steven J Shire
Mary B Sliwkowski
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO944752L publication Critical patent/NO944752L/no
Publication of NO944752D0 publication Critical patent/NO944752D0/no
Publication of NO318644B1 publication Critical patent/NO318644B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases RNAses, DNAses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/21Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001Deoxyribonuclease I (3.1.21.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/814Enzyme separation or purification
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/814Enzyme separation or purification
    • Y10S435/815Enzyme separation or purification by sorption

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO19944752A 1992-06-08 1994-12-08 Fremgangsmate omfattende separering av isoaspartatholdig og ikke-isoaspartatholdig human-DNase fra en blanding derav, renset isoaspartatholdig human-DNase og ikke-aspartatholdig human-DNase, farmasoytisk preparat samt anvendelse av preparatet ved fremstilling av et medikament for behandling av en pasient som har en akkumulering av purulent materiale eller pulmonar sykdom. NO318644B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/895,300 US5279823A (en) 1992-06-08 1992-06-08 Purified forms of DNASE
PCT/US1993/005136 WO1993025670A1 (en) 1992-06-08 1993-05-28 Purified forms of dnase

Publications (3)

Publication Number Publication Date
NO944752L NO944752L (no) 1994-12-08
NO944752D0 true NO944752D0 (no) 1994-12-08
NO318644B1 NO318644B1 (no) 2005-04-25

Family

ID=25404292

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19944752A NO318644B1 (no) 1992-06-08 1994-12-08 Fremgangsmate omfattende separering av isoaspartatholdig og ikke-isoaspartatholdig human-DNase fra en blanding derav, renset isoaspartatholdig human-DNase og ikke-aspartatholdig human-DNase, farmasoytisk preparat samt anvendelse av preparatet ved fremstilling av et medikament for behandling av en pasient som har en akkumulering av purulent materiale eller pulmonar sykdom.

Country Status (30)

Country Link
US (4) US5279823A (no)
EP (2) EP1013284B1 (no)
JP (1) JP3383307B2 (no)
KR (2) KR100302092B1 (no)
AT (2) ATE195340T1 (no)
AU (1) AU682822B2 (no)
BG (1) BG62335B1 (no)
BR (1) BR9306670A (no)
CA (1) CA2137237C (no)
CZ (1) CZ293105B6 (no)
DE (3) DE4392749T1 (no)
DK (1) DK0644932T3 (no)
ES (1) ES2150447T3 (no)
FI (1) FI945549A0 (no)
GB (1) GB2282140B (no)
GE (1) GEP20002300B (no)
GR (1) GR3034718T3 (no)
HU (1) HU219549B (no)
IL (1) IL105724A (no)
MD (1) MD960288A (no)
NO (1) NO318644B1 (no)
NZ (1) NZ253559A (no)
PL (1) PL175873B1 (no)
PT (1) PT644932E (no)
RO (1) RO117188B1 (no)
RU (1) RU2238320C2 (no)
SK (1) SK282957B6 (no)
TJ (1) TJ396B (no)
UA (1) UA46693C2 (no)
WO (1) WO1993025670A1 (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE176924T1 (de) * 1988-12-23 1999-03-15 Genentech Inc Verfahren zur herstellung von menschlicher dnase
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
ATE268605T1 (de) * 1994-03-04 2004-06-15 Genentech Inc Pharmazeutische akzeptabel dnase zusammensetzung
JP3009224B2 (ja) * 1994-03-04 2000-02-14 ジェネンテック インコーポレイテッド 改良されたdnアーゼ液体溶液
JPH09512715A (ja) * 1994-05-05 1997-12-22 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド ヒトdnase
US6251648B1 (en) 1998-04-03 2001-06-26 Human Genome Sciences, Inc. Gene encoding human Dnase
US5830744A (en) * 1995-06-06 1998-11-03 Human Genome Sciences, Inc. Gene encoding human Dnase
US5602110A (en) * 1994-08-31 1997-02-11 Case Western Reserve University Method and composition for treating cystic fibrosis
WO1996007735A1 (fr) * 1994-09-06 1996-03-14 Seiichi Tanuma Nouvelle desoxyribonuclease
US5863563A (en) * 1994-10-20 1999-01-26 Alphagene Inc. Treatment of pulmonary conditions associated with insufficient secretion of surfactant
US6348343B2 (en) 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
SK284191B6 (sk) 1995-02-24 2004-10-05 Genentech, Inc. Aktín-rezistentný variant humánnej DNázy I
NZ331063A (en) * 1996-02-05 2000-03-27 Inc Genentech Isolated nucleotide sequences encoding for mature LS- DNase which is resistant to actin inhibition
US6482626B2 (en) * 1996-02-05 2002-11-19 Genentech, Inc. Human DNase
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
ATE370961T1 (de) * 1998-05-06 2007-09-15 Genentech Inc Reinigung von antikörpern durch ionenaustauschchromatographie
US8820316B2 (en) * 2000-02-11 2014-09-02 Respironics Respiratory Drug Delivery (Uk) Ltd Drug delivery apparatus
CA2635489A1 (en) * 2000-02-11 2001-08-16 Respironics Respiratory Drug Delivery (Uk) Ltd Drug delivery apparatus
ES2312447T3 (es) * 2000-05-31 2009-03-01 Novartis Vaccines And Diagnostics, Inc. Procedimiento para la purificacion de particulas de replicon alfavirus.
MD20010375A (ro) * 2001-11-19 2003-06-30 АНДРИЕВСКИ Сергей Malaxor
MD2260C2 (ro) * 2001-11-22 2004-03-31 АНДРИЕВСКИ Сергей Malaxor
HUE033623T2 (en) 2002-09-11 2017-12-28 Genentech Inc protein purification
US7067298B2 (en) * 2003-03-31 2006-06-27 Ambion, Inc. Compositions and methods of using a synthetic Dnase I
US7595179B2 (en) 2004-04-19 2009-09-29 Applied Biosystems, Llc Recombinant reverse transcriptases
US20080160577A1 (en) * 2005-02-04 2008-07-03 Glaxo Group Limited Optimization of Heterologous Polypeptide Expression
KR100655438B1 (ko) * 2005-08-25 2006-12-08 삼성전자주식회사 자기 기억 소자 및 그 형성 방법
WO2007143206A2 (en) * 2006-06-02 2007-12-13 Epicentre Technologies Compositions and methods for removal of dna from a sample
WO2008047364A2 (en) * 2006-10-18 2008-04-24 Periness Ltd. Method and pharmacological composition for the diagnosis and treatment of male sub-fertility
HUE037409T2 (hu) 2007-10-30 2018-08-28 Genentech Inc Antitest-tisztítás kationcserés kromatográfiával
WO2009123950A2 (en) * 2008-03-31 2009-10-08 The Trustees Of The University Of Pennsylvania Chimera comprising bacterial cytotoxin and methods of using the same
GB2474225A (en) * 2009-07-21 2011-04-13 Biotec Pharmacon Asa DNase for decontamination of reverse transcription and amplification reactions
EP2699680B1 (en) 2011-04-21 2017-12-27 University of Massachusetts Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
US20150010527A1 (en) * 2012-02-01 2015-01-08 Protalix Ltd. Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
CN103920144B (zh) * 2013-01-15 2016-09-14 吴庄民 重组人的脱氧核糖核酸酶i的新应用
WO2015200645A1 (en) 2014-06-25 2015-12-30 Jhl Biotech, Inc. Methods and reagents for purification of proteins
WO2016067944A1 (ja) 2014-10-31 2016-05-06 Jcrファーマ株式会社 組換えヒトDNaseIの製造方法
CA2988471A1 (en) * 2015-07-28 2017-02-02 University Of Massachusetts Transgenic expression of dnase i in vivo delivered by an adeno-associated virus vector
EP4094780A3 (en) 2016-02-12 2023-02-08 University of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
JP7125392B2 (ja) 2016-11-17 2022-08-24 アイオバンス バイオセラピューティクス,インコーポレイテッド レムナント腫瘍浸潤リンパ球並びにそれを調製及び使用する方法
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
US20230226138A1 (en) 2020-06-01 2023-07-20 Black Cat Bio Limited Compositions and methods for treating infections and netopathy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2801956A (en) * 1954-08-24 1957-08-06 Merck & Co Inc Process for preparing pancreatic desoxyribonuclease
US2834710A (en) * 1955-06-29 1958-05-13 Merck & Co Inc Pancreatic desoxyribonuclease penicillin composition and process of preparation
US3208908A (en) * 1961-11-16 1965-09-28 Parke Davis & Co Fibrinolysin-desoxyribonuclease for enzymatic debridement
US3663690A (en) * 1969-08-12 1972-05-16 Hoechst Co American Mucolytic composition and method of treatment of broncho-pulmonary disorders therewith
CA1059937A (en) * 1975-03-25 1979-08-07 Boen T. Khouw Isolation and purification of deoxyribonuclease
US5077211A (en) * 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
ATE176924T1 (de) * 1988-12-23 1999-03-15 Genentech Inc Verfahren zur herstellung von menschlicher dnase
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE

Also Published As

Publication number Publication date
NO944752L (no) 1994-12-08
DE69334317D1 (de) 2010-03-11
FI945549A (fi) 1994-11-25
GB9423695D0 (en) 1995-01-11
WO1993025670A1 (en) 1993-12-23
GB2282140A (en) 1995-03-29
RO117188B1 (ro) 2001-11-30
DK0644932T3 (da) 2001-01-02
BR9306670A (pt) 1998-12-08
DE69329200D1 (de) 2000-09-14
PL175873B1 (pl) 1999-02-26
BG62335B1 (bg) 1999-08-31
US5783433A (en) 1998-07-21
US5279823A (en) 1994-01-18
JPH07507455A (ja) 1995-08-24
BG99234A (bg) 1995-07-28
UA46693C2 (uk) 2002-06-17
TJ396B (en) 2004-12-29
HUT70468A (en) 1995-10-30
RU94046424A (ru) 1997-03-10
EP0644932B1 (en) 2000-08-09
EP1013284B1 (en) 2010-01-20
FI945549A0 (fi) 1994-11-25
GR3034718T3 (en) 2001-01-31
US6440412B1 (en) 2002-08-27
DE4392749T1 (de) 1995-07-20
HU9403512D0 (en) 1995-02-28
CZ293105B6 (cs) 2004-02-18
ES2150447T3 (es) 2000-12-01
EP0644932A1 (en) 1995-03-29
CA2137237C (en) 2004-10-26
EP1013284A2 (en) 2000-06-28
NZ253559A (en) 1996-11-26
DE69329200T2 (de) 2001-04-26
IL105724A0 (en) 1993-09-22
RU2238320C2 (ru) 2004-10-20
CZ303294A3 (en) 1995-06-14
CA2137237A1 (en) 1993-12-23
IL105724A (en) 1997-06-10
ATE455557T1 (de) 2010-02-15
SK282957B6 (sk) 2003-01-09
MD960288A (ro) 1998-01-31
AU4398193A (en) 1994-01-04
GB2282140B (en) 1996-04-17
PT644932E (pt) 2001-02-28
US20030077267A1 (en) 2003-04-24
US6932965B2 (en) 2005-08-23
NO318644B1 (no) 2005-04-25
KR100323357B1 (ko) 2002-02-19
SK149594A3 (en) 1996-01-10
HU219549B (hu) 2001-05-28
AU682822B2 (en) 1997-10-23
GEP20002300B (en) 2000-11-25
EP1013284A3 (en) 2000-08-30
JP3383307B2 (ja) 2003-03-04
KR100302092B1 (ko) 2001-10-22
ATE195340T1 (de) 2000-08-15

Similar Documents

Publication Publication Date Title
NO944752L (no) Rensede DNase-former
FI862011A0 (fi) Terapeutiska nukleosider.
HUP0100815A2 (hu) Neurológiai és neuropszichiátriai rendellenességek kezelésére szolgáló gyógyszerkészítmények
ATE142877T1 (de) Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie
BG86132A (bg) Производни на пиридазинамин
ATE83659T1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
DE3776946D1 (de) Nasale verabreichung von arzneimitteln.
ATE73331T1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
DE3688038D1 (de) Verwendung von buspiron zur herstellung von pharmazeutischen zusammensetzungen zur linderung von krankhaften angst.
HUP0104410A2 (hu) Ateroszklerózis megelőzésére és/vagy kezelésére szolgáló gyógyszerkészítmények
DE3875769D1 (de) Therapeutische nukleoside.
DE3884680D1 (de) Äusseres Membranprotein F von Pseudomonas aeruginosa.
DK347289D0 (da) Terapeutiske forbindelser
ATE181239T1 (de) Verwendung von biertreberextrakt zur herstellung von oral zu verabreichenden zubereitungen

Legal Events

Date Code Title Description
MK1K Patent expired